Researchers at Mayo Clinic presented data at DDW 2026 demonstrating that the TissueCypher molecular test enhances risk stratification for Barrett's esophagus patients. The test better predicts progression to serious conditions like high-grade dysplasia or esophageal cancer compared to traditional methods, leading to changes in surveillance intervals for over half of patients. This allows for more personalized, risk-aligned management, potentially improving outcomes by escalating care for higher-risk patients and reducing unnecessary procedures for lower-risk individuals. The findings support integrating TissueCypher into clinical practice to guide more effective patient monitoring and treatment decisions.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
Girard Sharp LLP is investigating potential securities claims for former Discover investors who received Capital One shares after Capital One acquired Discover in May 2025. Since the merger, Capital One's stock price has declined, leading to possible...
Sunshine Silver, a mining and refining company based in Idaho, is preparing for a $2.32 billion initial public offering on the New York Stock Exchange. The company aims to raise up to $330 million by selling 20 million shares priced between $13.50 an...
